Back to Search
ANGELA DEMICHELE, MD
MD
Medical Oncology Physician
NPI: 1528099322IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
MD051248L(PA)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Class of 1991
Research & Publications (20)
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
PMID 19435922·Cancer Res·2009
8-other
Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.
PMID 18757329·J Clin Oncol·2008
8-other
Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
PMID 14633738·Cancer Res·2003
8-other
Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients.
PMID 12712466·Cancer·2003
8-other
Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
PMID 19376514·Fertil Steril·2010
8-other
Delivery of survivorship care by primary care physicians: the perspective of breast cancer patients.
PMID 19139437·J Clin Oncol·2009
8-other
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
PMID 19124504·Cancer Epidemiol Biomarkers Prev·2009
4-observational
Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms.
PMID 19064976·J Clin Oncol·2009
8-other
Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women.
PMID 19028704·Carcinogenesis·2009
8-other
Optimizing outcomes with bevacizumab by better targeting patients and tumors.
PMID 19476263·Oncology (Williston Park)·2009
8-other
Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors.
PMID 19679620·Integr Cancer Ther·2009
3-trial
Genomic predictors of outcome and treatment response in breast cancer.
PMID 19537843·Mol Diagn Ther·2009
6-review
Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors.
PMID 19517460·Cancer·2009
8-other
Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications.
PMID 19235785·Cancer·2009
8-other
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.
PMID 18458333·Proc Natl Acad Sci U S A·2008
8-other
Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk.
PMID 17548708·Cancer Epidemiol Biomarkers Prev·2007
8-other
Telomerase-specific T-cell immunity in breast cancer: effect of vaccination on tumor immunosurveillance.
PMID 17974999·Cancer Res·2007
8-other
Pharmacogenetic modulation of combined hormone replacement therapy by progesterone-metabolism genotypes in postmenopausal breast cancer risk.
PMID 17827444·Am J Epidemiol·2007
8-other
Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology.
PMID 17372239·Cancer Epidemiol Biomarkers Prev·2007
8-other
Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
PMID 17293384·Cancer Res·2007
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3400 SPRUCE ST., 14 PENN TOWER
PHILADELPHIA, PA 19104 - Phone
- (215) 349-5730
Quick Facts
- NPI
- 1528099322
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 35
- Publications
- 20
Are you this provider?
Claim Your Profile